SOPHiA GENETICS

SOPHiA GENETICS Enterprise Value

The Enterprise Value (EV) of SOPHiA GENETICS (SOPH) as of Oct 23, 2026 is 301.74 M USD. In the previous year, Enterprise Value (EV) was 271.40 M USD — a change of 11.18% (higher).

Enterprise Value

301.74 MUSD

YoY

11.18%

Last updated:

Enterprise Value (EV) of SOPHiA GENETICS is 2025 301.74 M USD. Enterprise Value (EV) of SOPHiA GENETICS was 2024 271.40 M USD. It decreases by 11.18% higher compared to the previous year.

The SOPHiA GENETICS Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2019
311.66 M USD
Jan 1, 2020
231.45 M USD
Jan 1, 2021
69.38 M USD
Jan 1, 2022
159.68 M USD
Jan 1, 2023
216.95 M USD
Jan 1, 2024
271.40 M USD
Jan 1, 2025
301.74 M USD
The SOPHiA GENETICS Enterprise Value history
YEAREnterprise ValueYoY
301.74 MUSD+11.18%
271.40 MUSD+25.10%
216.95 MUSD+35.86%
159.68 MUSD+130.17%
69.38 MUSD-70.03%
231.45 MUSD-25.74%
311.66 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SOPHiA GENETICS Stock analysis

What does SOPHiA GENETICS do? Sophia Genetics SA is a Swiss company that was founded in 2011. The idea behind it was to improve genome sequencing and data analysis in order to make faster and more precise medical diagnoses. Sophia Genetics has since become a leading provider of artificial intelligence and data analysis in the medical field. The business model of Sophia Genetics is based on providing doctors and medical facilities with corresponding data analysis tools and platforms. Sophia Genetics' algorithms help to identify genetic anomalies and develop personalized therapies. This personalized medicine aims to improve healthcare. Sophia Genetics is divided into various sectors. The core sectors include oncology, pediatrics, cardiology, and neurology. In these specialized fields, Sophia Genetics' platforms and tools are used to optimize genome sequencing and data analysis, thus enabling faster and more precise diagnoses. The company offers a variety of products that help doctors and medical facilities create successful diagnoses and therapies. Sophia Genetics' flagship product is the Sophia Artificial Intelligence (AI) platform. This platform is used by doctors, clinics, and research institutions to analyze complex data and identify the genetic causes of diseases. The Sophia AI platform provides fast, precise, and secure genome sequencing and data analysis. Sophia Genetics also offers the Sophia DDM system. The DDM system is a cloud-based data exchange system that provides doctors and medical facilities with a secure way to exchange confidential medical data. The system also allows for the collection and analysis of information about diseases and disease progression in the population, in order to enable better healthcare. Another important product of Sophia Genetics is the Sophia Hereditary Cancer Solution. This product helps in the early detection of hereditary cancer. The Sophia Hereditary Cancer Solution provides fast and precise genetic diagnostics to identify family members at increased risk of cancer and take appropriate measures. Another product of Sophia Genetics is Sophia Radiomics. This software uses artificial intelligence and machine learning to detect and characterize diseases based on X-ray and CT scans. By analyzing large amounts of data, the Sophia Radiomics software can assist doctors in making more precise diagnoses and better treatment decisions. Sophia Genetics relies on close collaboration with medical facilities and research institutions worldwide. The company now has customers in over 60 countries and is a partner to more than 1,000 hospitals worldwide. Sophia Genetics' platforms and tools have already helped many people to be diagnosed and treated faster and more accurately. Overall, Sophia Genetics is an innovative company that has revolutionized medical diagnostics. With its advanced platforms and tools, the company provides doctors and medical facilities with an excellent opportunity to develop personalized therapies and enable better healthcare. SOPHiA GENETICS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SOPHiA GENETICS stock

Enterprise Value (EV) of SOPHiA GENETICS is 301.74 M USD in 2025.

Enterprise Value (EV) of SOPHiA GENETICS changed from 271.40 M USD to 301.74 M USD, representing a 11.18% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) SOPHiA GENETICS since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s USD, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' USD varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s SOPHiA GENETICS with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — SOPHiA GENETICS

All Key Metrics — SOPHiA GENETICS